Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease:The Gut and Obesity Asia initiative

查看全文 作　　者：Panyavee [1]Pitisuttithum;Wah-Kheong [2]Chan;George Boon-Bee [3]Goh;Jian-Gao [4]Fan;Myeong Jun [5]Song;Phunchai [6]Charatcharoenwitthaya;Ajay [7]Duseja;Yock-Young [8]Dan;Kento [9]Imajo;Atsushi [9]Nakajima;Khek-Yu [8]Ho;Khean-Lee [2]Goh;Vincent Wai-Sun [10]Wong;Sombat [1]Treeprasertsuk

机构地区：[1]Department of Medicine,Faculty of Medicine,Chulalongkorn University,Bangkok 10330,Thailand;[2]Department of Medicine,University of Malaya,Kuala Lumpur 50603,Malaysia;[3]Department of Gastroenterology&Hepatology,Singapore General Hospital,Singapore 169608,Singapore;[4]Department of Gastroenterology,Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China;[5]Department of Internal Medicine,The Catholic University of Korea,Daejeon 301-723,South Korea;[6]Division of Gastroenterology,Faculty of Medicine Siriraj Hospital,Mahidol University,Bangkok 10700,Thailand;[7]Department of Hepatology,Post Graduate Institute of Medical Education and Research,Chandigarh 160012,India;[8]Department of Medicine,National University of Singapore 119228,Singapore;[9]Department of Gastroenterology and Hepatology,Yokohama City University Graduate School of Medicine,Yokohama 236-0004,Japan;[10]Department of Medicine and Therapeutics,The Chinese University of Hong Kong,Hong Kong 999077,China

出　　处：《World Journal of Gastroenterology》索引2020年第26卷第19期,共11页

摘　　要：BACKGROUND Gamma-glutamyl transferase(GGT)is associated with the risk of cardiovascular disease(CVD)in the general population.AIM To identify the association of baseline GGT level and QRISK2 score among patients with biopsy-proven nonalcoholic fatty liver disease(NAFLD).METHODS This was a retrospective study involving 1535 biopsy-proven NAFLD patients from 10 Asian centers in 8 countries using data collected by the Gut and Obesity in Asia(referred to as“GO ASIA”)workgroup.All patients with available baseline GGT levels and all 16 variables for the QRISK2 calculation(QRISK2-2017;developed by researchers at the United Kingdom National Health Service;http://gffzz3d3435dbdf8b436dsv6kbcnwuown66q00.ffgz.tsg.suse.edu.cn/2017/;10-year cardiovascular risk estimation)were included and compared to healthy controls with the same age,sex,and ethnicity.Relative risk was reported.QRISK2 score>10%was defined as the high-CVD-risk group.Fibrosis stages 3 and 4(F3 and F4)were considered advanced fibrosis.RESULTS A total of 1122 patients(73%)had complete data and were included in the final analysis;314(28%)had advanced fibrosis.The median age(interquartile range[IQR])of the study population was 53(44-60)years,532(47.4%)were females,and 492(43.9%)were of Chinese ethnicity.The median 10-year CVD risk(IQR)was 5.9%(2.6-10.9),and the median relative risk of CVD over 10 years(IQR)was 1.65(1.13-2.2)compared to healthy individuals with the same age,sex,and ethnicity.The high-CVD-risk group was significantly older than the low-risk group(median[IQR]:63[59-67]vs 49[41-55]years;P<0.001).Higher fibrosis stages in biopsy-proven NAFLD patients brought a significantly higher CVD risk(P<0.001).Median GGT level was not different between the two groups(GGT[U/L]:Median[IQR],high risk 60[37-113]vs low risk 66[38-103],P=0.56).There was no correlation between baseline GGT level and 10-year CVD risk based on the QRISK2 score(r=0.02).CONCLUSION The CVD risk of NAFLD patients is higher than that of healthy individuals.Baseline GGT level cannot predict CVD risk in NAFLD patients.However,advanced fibrosis is a predictor of a high CVD risk. 关键词：Nonalcoholic fatty liver disease Gamma glutamyl transferase QRISK Cardiovascular risk Gut and Obesity in Asia

相关文献

参考文献（36）
引证文献（1）
耦合文献（13）

参考文献(36)

引证文献(1)

耦合文献(13)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease:The Gut and Obesity Asia initiative

参考文献(36)

引证文献(1)

耦合文献(13)

用户提示